INVOKAMET™ is the first fixed-dose combination of an SGLT2 inhibitor with metformin approved in the United States (Janssen)
Diabetes News Service
INVOKAMET™ is the first fixed-dose combination of an SGLT2 inhibitor with metformin approved in the United States (Janssen)
For iPhone and iPad | For Android devices
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
Website by Wired up Wales